
REVIEW
TheRoleofOATP1B1andBCRPinPharmacokineticsandDDIofNovelStatins
WenJinHua,WeiXiaoHua&HuJinFang
DepartmentofPharmacy,theFirstAf liatedHospitalofNanchangUniversity,Nanchang,China
Keywords
BCRP;DDIs;OATP1B1;pitavastatin;rosuvastatin;SNP.
Correspondence
WenJinHua,DepartmentofPharmacy,TheFirstAf liatedHospitalofNanchangUniversity,Nanchang,China.
Tel:+867916361194;Fax:+867916361195;E-mail:xyq2011@yahoo.cn
SUMMARY
TheaimofthisreviewistoprovideusefulinformationnotonlyforstudyingtheeffectofOATP1B1and/orBCRPgenemutationonpharmacokineticsofnovlestatinsofpitavastatinandrosuvastatinbutalsoforstudyingdrug–druginteractions(DDI)betweenthenovlestatinsandothersubstratesofOATP1B1and/orBCRP.Intra-andinter-ethnicdifferencesinpharmacokineticpro lesofclinicallyrelevantdrugsareimportantissuesreportedinmanypapersnotonlyforscenesofappropriatedrugusedinclinicalsettingsbutalsoforthoseofthedrugdevelopment.Pharmacogenomicsisextremelyusefulforunderstandingtheseracialdifferences.Recentpharmacogeneticsstudyhavedisclosedimpor-tantrolesofdrugtransportersinthepharmacokinetic(PK)pro lesofsomeclinicallyrelevantdrugs.Inthispresentation,weintroducesinglenucleotidepolymorphisms(SNPs)ofOATP1B1andBCRPandreviewthecontributionofgeneticpolymorphismsofthetransporterstothepharmacokineticsofdualsubstratesaspitavastatinandrosuvastatinfromrecentstudy.Atthesametime,theDDIsbetweenpitavastatinorrosuvastatinandotherdrughavebeenex-tensivelyconcernedbecauseofinhibitingOATP1B1-mediatedhepaticuptakeorBCRP-mediatedhepaticef uxofpitavastatinandrosuvastatin.ThisreviewsummarizedthecurrentstudiesabouttheroleofOATP1B1andBCRPinDDIsbetweenpitavastatinorrosuvastatinandotherclinicallyrelevantdrugs.TheroleofOATP1B1andBCRPgenemutationcanaffectthePKpro lesofpitavas-tatinandrosuvastatin.TheDDIsbetweenthenovlestatinsandothersubstratesofOATP1B1orBCRPmayoccurandcausechangeinthepharmacokineticofthenovlestatins.
doi:10.1111/j.1755-5922.2011.00290.x
Introduction
Transportersexpressedinvarioustissuesplayanimpor-tantroleindrugdispositionanddrugtransport.Drugsuptakeoref uxbytransportersisakeyprocessfortherelateddrugpharmacokinetics.TheHumanGeneNomenclatureCommittee(HGNC)hasclassi edtrans-portersbystandardizednamessuchasthesolutecarriersuperfamily(SLC)andATP-bindingcassettetransporters(ABC).Byregulatingthefunctionofsuchtransporters,itmaybepossibletoeventuallydevelopdrugswithidealpharmacokineticpro les.Thein uxandef uxtrans-porterslocatedeitheratthebasolateralorapicalmem-
braneinpolarizedcellswereclassi eddependonthedrugtransportmode.Forexample,intheliver,anuptaketransportersuchasorganicaniontransportingpolypep-tide1B1(formallyknownasOATP-CorOATP2,geneSLCO1B1/OATP1B1)mayextractitsdrugsubstratesfromtheportalbloodintohepatocytes,thenotherdrugtrans-porters,suchasbreastcancerresistanceprotein(BCRP/ABCG2)andmultidrugresistanceprotein1(MDR1,alsoknownasP-glycoprotein)maybeimportantinef uxofthemetaboliteorparentdrugsfromthehepatocyte[1].TherearemultipletransporterssuchasOATP1B1,OATP1B3,OATP2B1,OATP1A2,andBCRPmayinvolvedintheuptakeandef uxofdrugs.Thedrugtransporters
e234CardiovascularTherapeutics30(2012)e234–e241
ª2011BlackwellPublishingLtd
The role of OATPs in pharmacokinetics and drug–...OATPS AND LIPID-LOWERING DRUGS Statins, synthetic ...is the substrate of both OATP1B1 and OATP1B3....
Therefore, the pharmacokinetics of several important...Moreover, to check whether other statins could ...(E), both OATP1B1 and BCRP (F), both OATP1B...
BCRP The role of a basolateral transporter in rosuvastatin..., and OST? but not OATP1B1 and OATP1B3. cis...the pharmacokinetics of atorvastatin and rosuvas...
Effect of omeprazole on the pharmacokinetics and toxicities...(BCRP); APC, 7-ethyl-10-[4-N(5-...Role of CYP3A4 in the regulation of the aryl ...
Pharmacokinetics and Bioanalysis, AstraZeneca, Wilmington...Of all the commercially available statins, ...(G), or both OATP1B1 and BCRP (H) was ...
BCRP MDR1 MRP2 ADP BSEP Xenobiotics detoxification...2) The in vitro metabolism data on statins (...Effect of OATP1B1 genotypes on the pharmacokinetics...
pharmacokinetics in humans) Kazuya Maeda, Ph.D. ...(statins) (4)Prediction of in vivo clearance ...OATP1B1/BCRP The 1000 60 120 180 0 60 120 ...
pharmacokinetics in humans) Kazuya Maeda, Ph.D. ...(statins) (4)Prediction of in vivo clearance ...OATP1B1/BCRP The 1000 60 120 180 0 60 120 ...
热门文档